Pirello v. Qualitest Pharmaceuticals, Inc. | Search

Accessibility help Skip to navigation Skip to content Skip to footer

Showing results for Pirello v. Qualitest Pharmaceuticals, Inc.

Sort by

Viewing results 1‒25 of 29

Covid-19 vaccines
Pfizer and Moderna forecast to almost double vaccine sales in 2022
...Rivals AstraZeneca, Johnson & Johnson, Russia’s Sputnik V and new entrants such as Novavax make up the remainder of the market, which is forecast to double in value to $124bn next year....
October 18, 2021
Covid-19 vaccines
Africa will pay more for Russian Covid vaccine than ‘western’ jabs
...“Africa is a key market for Sputnik V,” said the Russian Direct Investment Fund, a Kremlin-run wealth fund overseeing Sputnik V’s foreign sales....
February 25, 2021
FT Live
US Pharma and Biotech Summit
Strategies for innovation, pricing and access
Thursday, 16 MayNew York, NY, USA
FT AlphavilleCoronavirus
The ESG case for the Oxford/AstraZeneca vaccine
...After such strong reads from the first two releases (three if we count Russia’s Sputnik V), the disappointing AZN figures were perhaps bound to prompt downward pressure on the company’s shares....
December 23, 2020
Coronavirus treatment
EU fast-tracks process for Pfizer and BioNTech’s Covid-19 vaccine
...In August, Russia became the first country to approve a Covid-19 vaccine — named Sputnik V — for civilian use, but western experts cast doubt on its efficacy and safety....
October 6, 2020
The Long ViewMichael Mackenzie
The coming earnings season could bring lofty stocks down to earth
...If there is a sense from this earnings season that confidence in a V-shaped recovery for profits is misplaced, then the impact will probably be hardest on companies with weak balance sheets, and on those...
July 11, 2020
News in-depthPharmaceuticals sector
Crispr puts first human in-body gene editing to test
...Beyond these three biotechs, Crispr could end up transforming the entire pharmaceutical industry....
January 7, 2020
FT Live
FTWeekend Festival: U.S. edition
Where the Financial Times weekend paper comes to life
Saturday, 4 MayThe REACH, at the Kennedy Center for the Performing Arts, F Street Northwest, Washington, DC, USA
Jonathan Guthrie
The fallacy behind the rise of passive fund management
...Their concentrated ownership of industries such as airlines and pharmaceuticals may push up travel and drug prices, some academics argue....
January 15, 2020
News in-depthCushman & Wakefield Inc
Cushman v the cleaner: the fight over non-competes
...She worked as a janitorial supervisor at C&W client Lonza, a Swiss pharmaceuticals group, which has a production facility in Portsmouth, New Hampshire....
October 16, 2018
Special Report50 Ideas to Change the World
Liver success holds promise of 3D organ printing
...He places human embryonic and pluripotent stem cells — that have the potential to grow into nearly every cell of the body — in tiny ‘U’ or ‘V’ shaped dishes in the lab to grow them into different types of...
March 5, 2018
News in-depthThe Big Read
Quantum computing: the power to think outside the box
...Pharmaceutical groups, which might see similar benefits from quantum technology in the long term, are still on the sidelines....
September 3, 2018
News in-depthThe Big Read
Big Tech vs Big Pharma: the battle over US patent protection
...Thanks to a series of court rulings since the mid-2000s, such as eBay v MercExchange in 2007, Mayo Collaborative Services v Prometheus Laboratories in 2012 and Alice Corp v CLS Bank in 2014, and the subsequent...
October 16, 2017
US & Canadian companies
Shire weighs spin-off for ADHD drugs division
...the neuroscience business should not “shock investors but is likely to raise a debate over possible use of proceeds should any cash be generated and management of any earnings dilution [ie deleveraging v...
August 3, 2017
News in-depthThe Big Read
Samsung: The activist v the ‘owners’
...Aberdeen Asset Management and Canada Pension Plan have also voiced opposition to the deal, as has the local company Ilsung Pharmaceuticals, which holds 2 per cent....
July 15, 2015
FT AlphavilleDavid Keohane
The 6am London Cut
...(Financial Times) Roche is to buy Santaris Pharma for up to $450m in the latest piece of dealmaking by the Swiss pharmaceuticals group....
August 5, 2014
UK economy
Raids seek to clamp down on fake drugs
...Just one of hundreds of raids carried out worldwide through Interpol’s Operation Pangea V, nearly 200 police and regulatory agencies combined efforts to clamp down on the complex multimillion dollar international...
October 4, 2012
FT Live
Global Private Banking Awards 2024
Celebrating excellence in wealth management
Thursday, 7 NovemberThe Landmark London, London, UK
beyondbricsNeil Munshi
Ranbaxy’s high blood pressure day
...beyondbrics India v China: a new race in biopharmaceuticals, beyondbrics...
November 30, 2011
Global Economy
Singapore economy contracts sharply in Q2
...Mr Paracuelles said he expected Japan to stage a V-shaped recovery in the second half of the year which would buoy Singapore’s economy....
July 14, 2011
IPOs
Apax plans for €11bn buy-out fund
...Apax is confident of raising a similar-sized fund to its last one, thanks to the €3.4bn it has returned to investors from realisations this year, including the $1.2bn sale of Qualitest Pharmaceuticals, the...
December 19, 2010
Mergers & Acquisitions
Buy-out activity rises with $2.5bn of exits
...Apax Partners of the UK has made a return of about 1.7 times its initial investment from the $1.2bn sale of Qualitest Pharmaceuticals, the US generic drugmaker, to its Nasdaq-listed rival Endo Pharmaceuticals...
September 28, 2010
Asia-Pacific equities
M&A activity to surge in China and India
...Examples include Astellas Pharma of Japan’s $3.8bn acquisition of OSI Pharmaceuticals in the US, and Korea National Oil’s $2.8bn deal with Britain’s Dana Petroleum....
February 10, 2011
US downturn
Consumer goods help US stocks shake off data
...In deals news, Endo Pharmaceuticals Holdings surged 8.1 per cent to $33.10 after it said it will buy privately owned generic drug manufacturer Qualitest Pharmaceuticals for about $1.2bn....
September 28, 2010
News in-depthUK economy
Raised spirits
...Economists dispute the nature of the recovery – is it a bounce-back “v” or a double-dip “w” – while old market hands caution that the summer rally could eventually give way to a correction....
September 11, 2009
US & Canadian companies
Court intervenes over US lawsuits
...The US Supreme Court decided to intervene in several important business disputes, on Friday, including lawsuits that could be worth billions of dollars to pharmaceutical and tobacco companies....
January 19, 2008
LexUK retail results
Merck v Schering
...Meanwhile Schering-Plough, its closest competitor for the US pharmaceutical limelight, got a slap in the face as slackening market share gains by its top cholesterol drugs extinguished high hopes for the...
October 24, 2007
New Technology Policy ForumTechnology sector
A dangerous one-two punch
...He has consulted frequently on both pharmaceutical and high tech issues....
October 24, 2007

Previous pagePage 1 of 2Next page